EUCTR2011-003032-31-DE进行中（未招募）不适用
A phase III 3 arms, multicenter, randomised, investigator-blind study to assess the efficacy and safety of ozenoxacin 1% cream applied twice daily for 5 days versus placebo in the treatment of patients with impetigo
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 465
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients will be entered into this study only if they meet all of the following criteria:
- •1. Written informed consent from the patient, legally acceptable representative or parent and able to follow study procedures.
- •2. Male and female patients =2 years of age.
- •3. Clinical diagnosis of bullous or non bullous impetigo. The patient has a total affected area comprised between 1-100 cm2 with surrounding erythema not extending more than 2 cm from the edge of any affected area. In case of multiple affected areas the total area will be the sum of each affected area and will not exceed 100 cm2. Additionally for patients < 12 years the total area will not exceed a maximum of 2% of the body surface area.
- •4. Total Skin Infection Rating Scale (SIRS) score of at least 8, including pus/exudate score of at least 1
- •5. Females of childbearing potential must use a reliable method of contraception (i.e. barrier type devices [e.g. female condom, diaphragm, contraceptive sponge] only in combination with a spermicide; intra-uterine devices; oral, injectable, transdermal or implantable contraceptives only in combination with a barrier method). Females are not of childbearing potential if they are pre-menarchical, postmenopausal (i.e. amenorrhea for at least 1 year prior to screening), or surgically sterile (tubal ligation and/or hysterectomy).
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 282
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients that meet any of the following criteria must not be enrolled in the study:
- •1. Has an underlying skin disease, such as pre-existing eczematous dermatitis, with clinical evidence of secondary infection.
- •2. Has a bacterial infection, which in the opinion of the investigator, could not be appropriately treated by a topical antibiotic.
- •3. Has systemic signs and symptoms of infection (e.g. a fever; defined as an axillary temperature over 37.2 °C (99.0 °F)
- •4. Documented or suspected bacteraemia.
- •5. Treatment with the following anti-infective agents prior to study drug administration: oral antibiotic within 7 days; topical antibiotic (at the investigational area(s) or within 5 cm from the edge of the investigational area(s)), within 7 days; a long-acting injectable antibiotic within 30 days.
- •6. Has applied any topical therapeutic agent (including, but not limited to, glucocorticoid steroids) directly to the impetigo lesions within 24 hours before entry into the study.
- •7. Has applied any topical (at the investigational area(s) or within 5 cm from the edge of the investigational area(s)) treatment with antiseptics (e.g. alcohol, chlorhexidine, hydrogen peroxide or iodine) or other treatment that in the investigator’s opinion could confound the evaluation of the treatment effect on the investigational area(s) within 8 hours before study start or planned treatment during the study.
- •8. Has taken any systemic or topical (at the investigational area(s) or within 5 cm from the edge of the investigational area(s)) treatment with analgesics, anti-inflammatory or antihistaminic within 8 hours before entry into the study.
- •9. Daily dose of >15 mg of systemic prednisone or equivalent for >10 days within the period starting 14 days prior to study drug administration or anticipated through the study period.
- •10. Known human immunodeficiency virus (HIV) infection, or evidence of clinically significant immunosuppression.
- •11. Current medical history of uncontrolled diabetes.
- •12. Is pregnant or lactating.
- •13. Known or suspected hypersensitivity to quinolones or any of the excipients in the cream of the investigational product.
- •14. Known or suspected hypersensitivity to retapamulin or any of the excipients in the ointment of the investigational product.
- •15. Underlying condition and/or disease that, according to the judgment of the Investigator, would be likely to interfere with completion of the course of study drug therapy or follow-up.
- •16. Have received treatment with any other investigational drug in the last 30 days before study entry.
- •17. Have previously been enrolled in this study.
研究者
相似试验
已完成
3 期
A Phase 3 clinical study to Evaluate the Efficacy and Safety of Tretinoin (Microsphere) 0.04% and Clindamycin 1% Combination Gel in Comparison to Tretinoin 0.025% Gel and Clindamycin 1% Gel in the treatment of patients with Acne (Pimples)CTRI/2014/08/004830Dr Reddys Laboratories Limited750
尚未招募
3 期
A study of Goserelin 10.8 mg Injection in comparison with the drug ZOLADEX® 10.8 mg Injection in patients with prostate cancer.CTRI/2020/02/023211Eurofarma Laboratrios SA
进行中（未招募）
1 期
To see how the medication MED2005 works (i.e. causes an erection) compared to placebo when applied to the penis by male volunteers who normally are unable to obtain an erectioEUCTR2017-000960-14-HUFutura Medical Developments Ltd.1,000
进行中（未招募）
1 期
To see how the medication MED2005 works (i.e. causes an erection) compared to placebo when applied to the penis by male volunteers who normally are unable to obtain an erectioEUCTR2017-000960-14-PLFutura Medical Developments Ltd.1,000
进行中（未招募）
1 期
To see how the medication MED2005 works (i.e. causes an erection) compared to placebo when applied to the penis by male volunteers who normally are unable to obtain an erectioErectile dysfunctionMedDRA version: 20.0Level: PTClassification code 10061461Term: Erectile dysfunctionSystem Organ Class: 10038604 - Reproductive system and breast disordersMedDRA version: 20.0Level: LLTClassification code 10015116Term: Erectile disturbanceSystem Organ Class: 10038604 - Reproductive system and breast disordersMedDRA version: 20.0Level: LLTClassification code 10025503Term: Male erectile disorderSystem Organ Class: 10038604 - Reproductive system and breast disordersMedDRA version: 20.0Level: LLTClassification code 10052003Term: Erectile dysfunction NOSSystem Organ Class: 10038604 - Reproductive system and breast disordersEUCTR2017-000960-14-LVFutura Medical Developments Ltd.1,000